Thin
1 / 2
Survodutide is a peptide compound designed as a GLP‑1/GIP/glucagon multi‑receptor agonist under clinical investigation for potential benefits in metabolic regulation, weight management, and glucose control.
It is being evaluated in clinical studies for its unique balanced receptor agonism profile.
Typical Human Clinical Dose (Investigational)
Once‑weekly subcutaneous administration is the regimen used in human Phase 2/3 studies.
Commonly studied doses include 2 mg, 4 mg, 6 mg, and 8 mg per week, with dose escalation based on tolerability and clinical endpoints.
These doses are for research purposes only and should only be administered under authorized clinical protocols.
Unlike some established peptide drugs with long‑standing granted patents, Survodutide’s patent landscape is still evolving. Careful review of publicly available patent databases reveals pending patent applications related to multi‑agonist peptide compositions and methods of use, but no single fully granted, composition‑of‑matter patent for Survodutide with a confirmed expiration date is currently available in the public domain.
